GB2323783A - Inhibitors of farnesyl protein transferase - Google Patents

Inhibitors of farnesyl protein transferase Download PDF

Info

Publication number
GB2323783A
GB2323783A GB9706652A GB9706652A GB2323783A GB 2323783 A GB2323783 A GB 2323783A GB 9706652 A GB9706652 A GB 9706652A GB 9706652 A GB9706652 A GB 9706652A GB 2323783 A GB2323783 A GB 2323783A
Authority
GB
United Kingdom
Prior art keywords
amino
methionine
mercaptopropylamino
gt
lt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB9706652A
Other versions
GB9706652D0 (en
Inventor
Jean-Louis Junien
David Alan Kendrick
Graeme Semple
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferring Bv Group Holdings
Original Assignee
Ferring Bv Group Holdings
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv Group Holdings filed Critical Ferring Bv Group Holdings
Priority to GB9706652A priority Critical patent/GB2323783A/en
Publication of GB9706652D0 publication Critical patent/GB9706652D0/en
Publication of GB2323783A publication Critical patent/GB2323783A/en
Application status is Withdrawn legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients

Abstract

Compounds for use as farnesyl protein transferase (FPT) inhibitors are described. Preferably these compounds are analogues of a motif "CaaX" wherein 'C' is cysteine, 'a' is an aliphatic amino acid, and 'X' is either methionine, serine or glutamine. Such compounds are intended for pharmaceutical use, particularly for the treatment of conditions having a T cell involvement, preferably inflammatory disorders.

Description

BACKGROUND The enzyme farnesyl protein transferase (EC 2.5.1 p21RAS famesyl transferase, FPlase) is a key component in the post-translational processing of a number of cellular proteins. It catalyses the reaction between farnesyl pyrophosphate and proteins which have as their Cterminal sequence a "CaaX" motif (where C is cysteine, a is an aliphatic aminoacid and X is one of a number of aminoacids including serine, methionine and glutamine). The outcome of the reaction is the formation of a thioether in which the farnesyl unit is covalently linked to the cysteine sulphur atom (Scheme 1). <img class="EMIRef" id="026450351-00010001" />

<tb>

<SEP> <SEP> 1 <SEP> o <SEP> +"Y,s-i" <tb> '0'il' <SEP> IPt <SEP> o~ <SEP> + <SEP> H <SEP> Ra <SEP> O <SEP> Ra <SEP> ORx0 <tb> <SEP> 0 <SEP> 0 <SEP> Ra <tb> <SEP> Farnesyl <SEP> pyroph <SEP> "OaaX" <SEP> protein <tb> <SEP> FPTase <tb> <SEP> ProteinsNtNottNXN > oH <tb> Amongst the most widely investigated families of protein substrates for FPTase are the products of the ras genes, p21N, including Kirsten (K-)ras, Harvey (Ha-)ras and N-ras.

Ras proteins are GTPases that control a number of intracellular signal transduction cascades. In order to function correctly, the ras proteins need to be localised at a cell membrane. The presence of a lipophilic farnesyl group at the C-terminus is a key determinant for effective translocation from the cytosol to the membrane, so inhibition of FPTase can result in failure of the protein to localise correctly and hence can lead to blockade of the downstream signals.

A number of groups have found inhibitors of Frvrase. The compounds that have been reported are structurally diverse. Many are analogues of the "CaaX' motif, a smaller number are analogues of farnesyl pyrophosphate or of the two substrates together, and a few have no obvious structural relationsip to either substrate. Representative examples are illustrated in the figures below.

FIGURE 1: CaaX ANALOGUES <img class="EMIRef" id="026450351-00030001" />

FIGURE 2: FARNESYL PYROPHOSPHATE ANALOGUES <img class="EMIRef" id="026450351-00040001" />

FIGURE 3: MISCELLANEOUS INHIBITORS <img class="EMIRef" id="026450351-00050001" />

The utility of these compounds has been studied particularly in the area of anti-cancer therapy. Ras mutations are prevalent in a number of tumours, and they are presumed to have a role in the etiology of the disease in these cases. FPTase inhibitors have been tried in animal models of cancer with good results. Experimental tumours regress during treatment and do not recur until the drug is withdrawn. Importantly, no drug toxicity is seen even after prolonged treatment. In consequence, it has been suggested that FPTase inhibitors have no effect on "normal" tissue (i.e. tissue that does not express mutant activated ras).

We have now found evidence that inhibitors of FPTase do have an effect on T lymphocytes which have no ras mutations. This unexpected finding suggests a new therapeutic role for FPTase inhibitors in the management of pathophysiological conditions in which there is involvement of T lymphocytes. These will typically be diseases which are characterised by an immunoinflammatory component, and include, for example, inflammatory bowel disease (ulcerative colitis and Crohn's disease), asthma and rheumatoid arthritis.

DETAILED DESCRIPTION OF THE INVENTION The invention described herein is a new use for a group of compounds which have been disclosed in the past. The compounds are characterised in that they are inhibitors of the enzyme famesyl protein transferase. The new use of these compounds is as therapeutic agents in the treatment of inflammatory diseases, particularly those involving an immune component. The invention is accordingly also a method of treatment for these disease conditions. Such conditions include, but are not limited to: ulcerative colitis, Crohn's disease, allergic rhinitis, graft-vs-host disease, conjunctivitis, asthma, rheumatoid arthritis, osteoarthritis, ARDS, Behcet's disease, transplant rejection, uticaria, allergic dermatitis, allopecia areata, scleroderma, exanthem, eczema, dermatomyositis, acne, diabetes, systemic lupus erythematosis, Kawasaki's disease, multiple sclerosis, emphysema, cystic fibrosis, chronic bronchitis and psoriasis. The compounds can also be used for the treatment of pain associated with inflammatory conditions.

The invention includes farnesyl protein transferase inhibitors that are analogues of the CaaX motif, analogues of the co-substrate farnesyl pyrophosphate, bisubstrate analogues, and natural and synthetic compounds that have little obvious structural analogy to either substrate. In particular it includes (but is not limited to): N-(2-(3-(N'-Cisteinyl-N'-methylamino)-4-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-1yl)acetyl)methionine N-(2-(3-(N'-Cysteinyl-N'-methylamino)-4-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-1yl)acetyl)methionine methyl ester N-(; (2' -Amino-3 ' -mercaptopropylamino)-2-phenylbenzoyl)methionine N-(4-(2'-Amino-3'-mercaptopropylamino)-2-phenylbenzoyl)methionien methyl ester 4-(2-Amino-3-mercaptopropylamino)biphenyl-3'-carboxylic acid (R*)-N-[[1,2,3,4-Tetrahydro-2-[N-(2-(1H-imidazol-4-yl)ethyl]-L-valyl]-3isoquinolinyl]carbonyl] -L-methionine N-((Famesylphosphonyloxy)acetyl)valyl-valyl-methionine N-(3-(Farnesylphosphonyl)propionyl)valyl-valyl-methionine N-(3-(Farnesylphosphonyl)propionyl)valyl-valyl-methionine methyl ester N-[2(S)-(2(R)-Amino-3-mercaptopropylamino)-3(S)-methylpentyl]isoleucyl-homoserine lactone N-[2(S)-(2(R)-Amino-3-mercaptopropylamino)-3(S)-methylpentyl]isoleucyl-homoserine N-[2(S)-(2(S)-(2(R)-Amino-3-mercaptopropylmino)-3(S)-methylpentyloxy)-3phenylpropionyl]methioninesulphone methyl ester N-[2(S)-(2(S)-(2(R)-Amino-3-mercaptopropylamino)-3(S )-methylpentyloxy)-3 phenylpropionyl]methioninesulphone N-[2(S)-(2(S)-(2(R)-Amino-3-mercaptopropylamino)-3(S)-methylpentyoxy)-3phenylpropionyl]methioninesulphone isopropyl ester 1 -(2-Amino-3-mercaptopropyl)-2- (2-methoxyethyl)-4- (1 -naphthoyl)piperazine 1-(2-Amino-3 -mercaptopropyl)-2-butyl-4- l-naphthoyl)piperazine N-((lR,2R,4E)-5- (2-Benzoxazolyl)- l-methyl-2-(3,4-methylenedioxyphenyl)pent4-enyl) 3,3-bis(carboxy)-N-(2-naphthylmethyl)glutaramic acid 1-(4-Pyridylacetyl)-4-(8-chloro-5,6-dihydro-11H-benzol[5,6]cycloheptat[1,2-b]pyridin-11ylidene)piperidine N-[2(S)-(2(R)-Amino-3-mercaptopropylamino)-3-methylbutyl]phenylalanyl-methionine N-(8-Amino-2-benzyl-9-mercapto-5-(2-propyl)non-6-enoyl)methionine N-(8-Amino-2-benzyl-9-mercapto-5-(2-propyl)non-Senoyl)methionine methyl ester The invention includes the use of medicinal formulations for the treatment of inflammatory diseases in which a compound as described above is used as an active principal. Such formulations will have as other ingredients such materials as bulking and binding agents and preservatives as are well known in the art The formulation may be a tablet, solution, suspension, aerosol, cream, suppository or any other form appropriate for the administration of the active principal. The administration can be topical, by intravenous, subcutaneous or intramuscular injection, or via the oral, opthalmological, nasal, bucal, rectal or vaginal routes.

When used to treat these conditions the amount of formulation (and hence the amount of active principal) will be chosen by the treating physician taking into account the age, weight and state of health of the patient as well as any other factors he considers to be relevant. The amount of active principal used will generally be between 0.1mug and 10g per day in a single dose or in divided doses. Preferably the amount will be between lmg and ig.

The efficacy of the compounds can be assessed in a number of assays using either isolated human T lymphocytes or whole animal models of immunoinflammation. Some of these assays are described in the following Examples.

EXAMPLE 1 Proliferation of T lymphocytes driven by CD3 Human T-lymphocytes are stimulated to proliferate with an anti-CD3 antibody in the presence of varying concentrations of the test compound. After 3 days [3]thymidine is added. The cells are incubated for a further 12 hours, then proliferation is quantified by counting the incorporation of radioactivity into the cellular fraction. The compounds of the invention inhibit proliferation at concentrations equal to or below 50pLM. Typical results are shown in the Table in which: Compound 1 is SCH-44342, more filly identified as 1 -(4-pyridylacetyl)-4-(8-chloro-5,6- dihydro- 1 lH-benzo[5 ,6] cyclohepta[ 1 ,2-b]pyridin- 11 -ylidene)piperidine, a farnesyl protein transferase inhibitor described by Bishop et al. (J.Biol.Chem. 1995, 270, 30611) Compound 2 is more flilly identified as 1-(2-amino-3-mercaptopropyl)-2-butyl-4-(1- naphthoyl)piperanne, a farnesyl protein transferase inhibitor described by Williams et al.

(J.Med.Chem. 1996, 39, 1345) <img class="EMIRef" id="026450351-00100001" />

<tb> <SEP> Concentration <SEP> (llM) <SEP> Inhibition <SEP> (%) <tb> Compound <SEP> 1 <SEP> 50 <SEP> 73 <tb> Compound <SEP> 2 <SEP> 1 <SEP> 41 <tb> EXAMPLE 2 Proliferation of T lymphocytes driven bv IL-2 Human T-lymphocytes are stimulated to proliferate with interleukin-2 in the presence of varying concentrations of the test compound. After 3 days [3H]thymidine is added. The cells are incubated for a further 12 hours, then proliferation is quantified by counting the incorporation of radioactivity into the cellular fraction. The compounds of the invention inhibit proliferation at concentrations equal to or below 50 M. Typical results are shown in the Table in which: Compound 1 is SCH-44342, more fully identified as 1-(4-pyridylacetyl)-4-(8-chloro-5,6 dihydro-l 1H-benzo[5,6]cycloheptal 1,Zb]pyridin-l l-ylidene)piperidine, a famesyl protein transferase inhibitor described by Bishop et al. (J.Biol.Chem. 1995, 270, 30611) Compound 2 is more flilly identified as 1-(2-amino-3-mercaptopropyl)-2-butyl-4-(1- naphthoyl)piperazine, a farnesyl protein transferase inhibitor described by Williams et al.

(J.Med.Chem. 1996, 39, 1345) <img class="EMIRef" id="026450351-00110001" />

<tb> <SEP> Concentration <SEP> ( M) <SEP> Inhibition <SEP> (%) <tb> Compound <SEP> 1 <SEP> 50 <SEP> 55 <tb> Compound <SEP> 2 <SEP> 1 <SEP> 72 <tb>

Claims (5)

C L A I M S:
1. The use, for the preparation of a medicament for the treatment of an inflammatory pathological condition or the associated pain, of inhibitor of farnesyl protein transferase.
2. The use of claim 1 in which the inflammatory condition has an immunological component.
3. The use of claim 1 or 2 in which the inflammatory tondition is ulcerative colitis, Crohn's disease, allergic rhinitis, graft-vs-host disease, conjunctivitis, asthma, rheumatoid arthritis, osteoarthritis, ARDS, Behcet's disease, transplant rejection, uticaria, allergic dermatitis, allopecia areata, scleroderma, exanthern, eczema, dermatomyositis, acne, diabetes, systemic lupus erythematosis, Kawasalå's disease, multiple sclerosis, emphysema, cystic fibrosis, chronic bronchitis or psoriasis.
4. The use of any preceding claim in which the inhibitor of farnesyl protein transferase is selected from: N-(2-(3-(N'-Cysteinyl-N'-methylamino)-4-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-1yl)acetyl)methionine, N-(2-(3-(N'-Cysteinyl-N'-methylamino)-4-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-1yl)acetyl)methionine methyl ester, N-(4-(2'-Amino-3'-mercaptopropylamino)-2-phenylbenzoyl)methionine, N-(4-(2'-Amino-3'-mercaptopropylamino)-2-phenylbezoyl)methionine methyl ester, $(2-Amino-3-mercaptopropylamino)biphenyl-3'-carboxylic acid, (R*)-N-[[1,2,3,4-Tetrahydro-2-[N-(2-(1H-imidazol-4-yl)ethyl]-L-valyl]-3isoquinolinyl]carbonyl]-L-methionine, N-((Famesylphosphonyloxy)acetyl)valyl-valyl-methionine, N-(3-(Famesylphosphonyl)propionyl)valyl-valyl-methionine N-(3-(Famesylphosphonyl)propionyl)valyl-valylmethionine methyl ester, N-[2(S)-(2(R)-Amino-3-mercaptopropylamino)-3(S)-methylpentyl]isoleucyl-homoserine lactone, N- [2(S > (2(R)-AmincF3-mercap topropylamino)-3 (S)-methylpentyl] isoleucyl-homoserine , N-[2(S)-(2(S)-(2(R)-Amino-3-mercaptopropylamino)-3(S )-methylpentyloxy)-3phenylpropionyl]methioninesulphone methyl ester, N-[2(S)-(2(S)-(2(R)-Amino-3-mercaptopropylamino)-3(S)-methylpentyloxy)-3phenylpropionyl]methioninesulphone, N-[2(S)-(2(S)-(2(R)-Amino-3-mercaptopropylamino)-3(S)-methylpentyloxy)-3phenylpropionyl]methioninesulphone isopropyl ester, 1-(2-Amino-3-mercaptopropyl)-2-(2-methoxyethyl)-4-(1-naphthoyl)piperazine, 1-(2-Amino-3-mercaptopropyl)-2-butyl-4-(1-naphthoyl)piperazine, N-((1R,2R,4E)(-5-(2-Benzoxazolyl)-1-methyl-2-(3,4-methylenedioxyphenyl)pent-4-enyl)3,3-bis(carboxy)-N-(2-naphthylmethyl)glutaramic acid, 1-(4-Pyridylacetyl)-4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11 ylidene)piperidine, N-[2(S)-(2(R)-Amino-3-mercaptopropylamino)-3-methbutyl]phenylalanyl-methionine, N-(8-Amino-2-benzyl-9-mercapto-5-(2-propyl)non-6-enoyl)methionine, and N-(8-Amino-2-benzyl-9-mercapto-5-(2-propyl)non-6-enoyl)methionine methly ester.
5. A method for the prevention or treatment of inflammatory pathological condition or the associated pain which comprises administering to the patient inhibitor of farnesyl protein transferase.
GB9706652A 1997-04-02 1997-04-02 Inhibitors of farnesyl protein transferase Withdrawn GB2323783A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB9706652A GB2323783A (en) 1997-04-02 1997-04-02 Inhibitors of farnesyl protein transferase

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9706652A GB2323783A (en) 1997-04-02 1997-04-02 Inhibitors of farnesyl protein transferase
AU68474/98A AU6847498A (en) 1997-04-02 1998-04-02 Anti-inflammatory medicament containing farnesyl protein transferase inhibitor, its preparation and use
PCT/GB1998/000976 WO1998043629A1 (en) 1997-04-02 1998-04-02 Anti-inflammatory medicament containing farnesyl protein transferase inhibitor, its preparation and use

Publications (2)

Publication Number Publication Date
GB9706652D0 GB9706652D0 (en) 1997-05-21
GB2323783A true GB2323783A (en) 1998-10-07

Family

ID=10810139

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9706652A Withdrawn GB2323783A (en) 1997-04-02 1997-04-02 Inhibitors of farnesyl protein transferase

Country Status (3)

Country Link
AU (1) AU6847498A (en)
GB (1) GB2323783A (en)
WO (1) WO1998043629A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071955A (en) * 1999-02-25 2000-06-06 The Regents Of The University Of California FXR, PPARA and LXRA activators to treat acne/acneiform conditions
WO2002040015A1 (en) * 2000-09-29 2002-05-23 Institute Of Ophthalmology Protein prenyl transferase inhibitors in the treatment of neuroinflammatory disease
EP1996183A1 (en) * 2006-03-20 2008-12-03 The University Of Queensland Method of treatment or prophylaxis inflammatory pain
US8404686B2 (en) 2004-12-24 2013-03-26 Spinifex Pharmaceuticals Pty Ltd Method of treatment or prophylaxis

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ509647A (en) * 1998-07-06 2003-12-19 Janssen Pharmaceutica Nv Farnesyl protein transferase inhibitors for treating arthropathies
AT323490T (en) * 2000-11-28 2006-05-15 Janssen Pharmaceutica Nv Farnesyl protein transferase hemmer for the treatment of inflammatory endurance
PT2362218E (en) 2004-11-05 2014-12-04 Janssen Pharmaceutica Nv Methods of monitoring the efficacy of farnesyltransferase inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089496A (en) * 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340828A (en) * 1991-09-30 1994-08-23 Merck & Co., Inc. Inhibitors of farnesyl protein transferase
US5736539A (en) * 1993-06-18 1998-04-07 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5574025A (en) * 1994-10-26 1996-11-12 Merck & Co., Inc. Inhibitors of prenyl-protein transferases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089496A (en) * 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071955A (en) * 1999-02-25 2000-06-06 The Regents Of The University Of California FXR, PPARA and LXRA activators to treat acne/acneiform conditions
WO2000049992A2 (en) * 1999-02-25 2000-08-31 The Regents Of The University Of California USE OF FXR, PPARα AND LXRα ACTIVATORS TO TREAT ACNE/ACNEIFORM CONDITIONS
WO2000049992A3 (en) * 1999-02-25 2001-04-12 Univ California USE OF FXR, PPARα AND LXRα ACTIVATORS TO TREAT ACNE/ACNEIFORM CONDITIONS
WO2002040015A1 (en) * 2000-09-29 2002-05-23 Institute Of Ophthalmology Protein prenyl transferase inhibitors in the treatment of neuroinflammatory disease
US8722675B2 (en) 2004-12-24 2014-05-13 Spinifex Pharmaceuticals Pty Ltd Method of treatment or prophylaxis
US8492382B2 (en) 2004-12-24 2013-07-23 Spinifex Pharmaceuticals Pty Ltd Method of treatment or prophylaxis
US8404686B2 (en) 2004-12-24 2013-03-26 Spinifex Pharmaceuticals Pty Ltd Method of treatment or prophylaxis
AU2007229322B2 (en) * 2006-03-20 2012-04-05 Novartis Ag Method of treatment or prophylaxis inflammatory pain
JP2013014591A (en) * 2006-03-20 2013-01-24 Spinifex Pharmaceuticals Pty Ltd Method of treatment or prevention of inflammatory pain
EP1996183A4 (en) * 2006-03-20 2010-04-14 Spinifex Pharm Pty Ltd Method of treatment or prophylaxis inflammatory pain
JP2009530315A (en) * 2006-03-20 2009-08-27 ザ・ユニバーシティ・オブ・クイーンズランド Methods for treating or preventing inflammatory pain
US8551950B2 (en) 2006-03-20 2013-10-08 Spinifex Pharmaceuticals Pty Ltd Method of treatment or prophylaxis of inflammatory pain
CN101443001B (en) 2006-03-20 2013-11-13 西芬克斯医药有限公司 Method of treatment or prophylaxis inflammatory pain
EP1996183A1 (en) * 2006-03-20 2008-12-03 The University Of Queensland Method of treatment or prophylaxis inflammatory pain
US9227968B2 (en) 2006-03-20 2016-01-05 Novartis Ag Method of treatment or prophylaxis of inflammatory pain

Also Published As

Publication number Publication date
WO1998043629A1 (en) 1998-10-08
AU6847498A (en) 1998-10-22
GB9706652D0 (en) 1997-05-21

Similar Documents

Publication Publication Date Title
Malawista Colchicine: a common mechanism for its anti‐inflammatory and anti‐mitotic effects
Goureau et al. Induction and regulation of nitric oxide synthase in retinal Müller glial cells
Majumdar et al. Methotrexate suppresses NF-κB activation through inhibition of IκBα phosphorylation and degradation
Minotti et al. The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase/iron regulatory protein-1 in cytosolic fractions from human myocardium
Caspary Sucrose malabsorption in man after ingestion of α-glucosidehydrolase inhibitor
US5703090A (en) Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
ES2256913T3 (en) Arginine antagonists for the inhibition of systemic hypotension associated with the production of nitric oxide or the endotelial derivative relaxation factor.
CA2255620C (en) Novel anandamide amidase inhibitors as analgesic agents
US6831082B2 (en) Method of using soluble epoxide hydrolase inhibitors
EP0866713B1 (en) Administration media for analgesic, anti-inflammatory and anti-pyretic drugs containing nitrous oxide and pharmaceutical compositions containing such media and drugs
Qiu et al. Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate
CN102933558B (en) As reverse amide compound and the using method thereof of protein deacetylase inhibitor
AU764262B2 (en) New dipeptidyl peptidase IV effectors
US6576646B1 (en) Methods for treating cognitive impairments caused by traumatic brain injuries
Perrella et al. Transforming growth factor-beta 1, but not dexamethasone, down-regulates nitric-oxide synthase mRNA after its induction by interleukin-1 beta in rat smooth muscle cells.
Slaff et al. Protease-specific suppression of pancreatic exocrine secretion
JP2005002129A (en) Allosteric adenosine receptor modulator
US5773231A (en) Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US20100056576A1 (en) Kinase inhibitors and methods of their use
AU729415B2 (en) Chemokine receptor antagonists and methods of use therefor
Sasaki et al. A single GTP-binding protein regulates K+-channels coupled with dopamine, histamine and acetylcholine receptors
Brown Matrix metalloproteinase inhibitors: a novel class of anticancer agents
BIRMELIN et al. Synthesis of prostanoids and cyclic nucleotides by phagocytosing rat Kupffer cells
DE602004009426T2 (en) Calcium channel blocker with two benzhydril parts
CN1072931C (en) Method of inhibiting cell-cell adhesion

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1015704

Country of ref document: HK